DRUG REGULATORY AUTHORITY OF PAKISTAN
DIVISION OF QUALITY ASSURANCE & LABORATORY TESTING

MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº II/S/10-26-45

DRUG PRODUCT DECLARED SUBSTANDARD BY DRUG TESTING LABORATORIES, PUNJAB.

Date: 23rd October, 2026

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments.
- Healthcare Professionals (Physicians, Pharmacists & Nurses).
- General Public.

Alert Summary:

Drug Testing Laboratories of Punjab Province informed that the samples of below mentioned drug products have been declared as '***Substandard***'.

S#	Product Name	Batch No.	Manufacturers	Remarks
1.	**Carapamin Injection** 200mg (Dopamine HydrochlorideUSP) Reg. No. 060235	26A059	M/s Caraway Pharmaceuticals, plot # 12, St. N-3, National Industrial Zone (RCCI) Rawat, Islamabad (DML # 000629)	The sample is declared as **Substandard** on the basis of content of organic impurities found above the allowed limits by DTL Punjab, Lahore.
2.	**Librax Tablet** (Chlordiazepoxide USP 5mg & Clinidium Bromide USP 2.5mg) Reg # 000568	001952	M/s Martin Dow Limited, plot # 37. Sector 19, Korangi Industrial Area, Karachi. (DML # 000267)	The sample is declared as **Substandard** on the basis of content of organic impurities found above the allowed limits by DTL Punjab, Faisalabad.

Risk Statement:

These products present a **moderate to high public health risk**, mainly affecting the **general population**, especially **cardiac patients, allergy sufferers, children, and chronic medicine users**. Moreover, the impurities may alter the stability of drug products and may cause formation of new complexes.

Action initiated: -

The Provincial Drug Control departments and DRAP's field offices have been asked to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores: -

All pharmacists and chemists working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s).

DRAP, Islamabad
+92 051 9255969
gsms@dra.gov.pk

Advice for Healthcare Professionals: -

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of above-mentioned products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers/general public: -

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using the drug products and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے